ArticleVaccine2012
LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Cell-Mediated and Peptide-Based Delivery Systems: Emerging Frontiers in Targeted Therapeutics.Pharmaceutics · 2025Review
- Advances and prospects of cell-penetrating peptides in tumor immunotherapy.Scientific reports · 2025Review
- Efficient Induction of Antigen-Specific CD8Pharmaceutics · 2022Article
- Genetic and Covalent Protein Modification Strategies to Facilitate Intracellular Delivery.Biomacromolecules · 2021Review
- Different Biological Activities of Histidine-Rich Peptides Are Favored by Variations in Their Design.Toxins · 2021Article
- Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.Journal of cellular physiology · 2020Review
- The Multifaceted Histidine-Based Carriers for Nucleic Acid Delivery: Advances and Challenges.Pharmaceutics · 2020Review
- The Utilization of Cell-Penetrating Peptides in the Intracellular Delivery of Viral Nanoparticles.Materials (Basel, Switzerland) · 2019Review
- Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.Scientific reports · 2019Article
- Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.Cellular and molecular life sciences : CMLS · 2018Review
- Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents.Molecules (Basel, Switzerland) · 2018Review
- pH-Dependent Membrane Interactions of the Histidine-Rich Cell-Penetrating Peptide LAH4-L1.Biophysical journal · 2017Article
- Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.Cancer immunology, immunotherapy : CII · 2016Article
- Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human Disease.International journal of molecular sciences · 2016Review
- Modular Vaccine Design Using Carrier-Free Capsules Assembled from Polyionic Immune Signals.ACS biomaterials science & engineering · 2015Article
- Lipid interactions of LAH4, a peptide with antimicrobial and nucleic acid transfection activities.European biophysics journal : EBJ · 2014Article
- Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2014Article
- Manipulating the pH response of 2,3-diaminopropionic acid rich peptides to mediate highly effective gene silencing with low-toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Control of pH responsive peptide self-association during endocytosis is required for effective gene transfer.Biochimica et biophysica acta · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
It is now clear that CD8+ T cells are crucial for therapeutic immunity against chronic viral infections and/or tumors. We reason that a strategy capable of improving CD8+ T cell activation would improve the efficacy of protein-based vaccines, which predominantly generate CD4+ T cell-mediated responses. Herein, we explore the ability of a novel cell-penetrating peptide (CPP), LAH4, to facilitate intracellular delivery of protein-based vaccines adjuvanted with Toll-like receptor 9 agonist CpG oligonucleotide (CpG) to generate enhanced CD8+ T cell immune responses and antitumor effects. LAH4 was found to mediate the intracellular delivery of both protein and nucleotide cargo and facilitate protein internalization using mechanisms involving endosomal acidification and processing through the proteasome pathway, leading to enhanced cross presentation of protein antigen by dendritic cells to CD8+ T cells. LAH4 also improved the internalization of CpG, resulting in NFkB activation, thus potentiating the adjuvant effect of CpG. We found that protein-based vaccine comprised of LAH4 mixed with model antigen and CpG generated significantly improved antigen-specific CD8+ T cell immune responses and/or antitumor effects. Furthermore, we found that LAH4 was able to enhance the ability of a tyrosinase-related protein 2 (TRP-2) peptide-based vaccine to generate TRP2-specific CD8+ T cells and antitumor effects against TRP2-expressing tumors. Thus, our results suggest that CPP technology using LAH4 is able to enhance both protein-based and peptide-based vaccine potency to generate antigen-specific CD8+ T cells and antitumor effects. Our findings serve as an important foundation for future clinical applications of CPP technology to improve protein/peptide-based vaccine potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.